Another study examined TNF-related apoptosis-inducing ligand (TRAIL) as a promising anticancer agent that has a similar limitation of acquired drug resistance and found that combinatory treatment of NF-κB inhibitors and TRAIL was able to reverse resistance and reduce tumor growth [85]. Here, TNFSF10 is linked to neoplasm.